Zalicus Shifts Gears to Pain After Phase IIb Miss in RA
Zalicus Inc., of Cambridge, Mass., is immediately terminating its development program for Synavive after a Phase IIb trial in rheumatoid arthritis failed to show meaningful clinical benefit compared to prednisolone, the active glucocorticoid component of the drug.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST